Clinical Trial Update: RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients [Phase 2]

View source ↗

Summary

Phase 2 RM-493 (setmelanotide) trial in patients with POMC deficiency, LEPR deficiency, or PCSK1 deficiency. The current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptin Receptor Deficiency
• Pcsk1 Deficiency
• Pomc Deficiency

Drugs mentioned

• IMCIVREE (setmelanotide)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Homozygous or Compound Heterozygous POMC, LEPR or PCSK1 Gene Mutation | Phase 2 | Status: UNKNOWN